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Introduction 
In the European Union 34.8 million women aged 15 to 64 are reported to have ever tried an illicit 
drug, compared with 54.3 million men (EMCDDA, 2016a). Although there are some methodological 
differences between surveys, data from the latest general population studies available from the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Statistical Bulletin (2016) 
indicate variations between countries in the lifetime rates of any illicit drug use among this group of 
women (see Figure 1). The highest rates are found in France (33 %), Denmark (30 %) and the United 
Kingdom (29 %) and the lowest levels are reported in Malta (1 %), Turkey (2 %) and Greece (4 %). 
Drug use rates within countries are higher among younger than older women (EMCDDA, 2016b). 
 
Figure 1. Illicit drug use: lifetime prevalence in the general population 
Data source: EMCDDA Statistical Bulletin (EMCDDA, 2016b). 
 
Figure 1 also highlights country-level variations in the drug use gender gap. Gender differences in 
drug use rates are wider in the case of intensive and regular drug use (Montanari, 2015) and 
narrower among younger than among older age groups (EMCDDA, 2016b). Trend data (see Figure 2) 
from the European School Survey Project on Alcohol and Other Drugs (ESPAD) show a recent 
narrowing of differences in the percentage of boys and girls aged 15 and 16 who use illicit drugs 
(ESPAD group, 2016). Again, differences are observed between countries, with lifetime prevalence 
rates being equal or slightly higher among girls than among boys in the Czech Republic, the Faroes, 
Malta and Iceland. ESPAD data indicate marked differences in the male to female gender ratio in 
Georgia and Albania (ESPAD and EMCDDA, 2017). 
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Figure 2. Illicit drug use: lifetime prevalence among 15-16 year old students  
 
Source: ESPAD 2015 (ESPAD group, 2016). 
 
Women make up approximately a quarter of all people with serious problems related to the use of 
illicit drugs and 20 % of all specialised treatment entrants (EMCDDA, 2016a). Some analyses show 
that women are more likely to access treatment, which may be due to the availability of specific 
services for women or treatment needs arising from pregnancy or parenting (EMCDDA, 2006). Other 
studies show that women may be less likely to seek specialised services than men, which may be 
linked to treatment barriers, including associated stigma (EMCDDA, 2006; Grella, 2015). In addition, 
women may be more likely to attribute their problems to physical or mental health issues and 
therefore seek care within these sectors (Greenfield et al., 2003). The extent and nature of the 
treatment gaps within different regions and subgroups in Europe is an area that requires further 
study that will need to take into account possible gender differences in underlying data quality. 
 
Women and men who use drugs differ in various aspects, including social characteristics, 
consequences of substance use and development and progression to dependence (Tuchman, 2010); 
and women present unique concerns that are sex and gender based (NIDA, 2016). Despite these 
differences, many drug use interventions are male oriented (EMCDDA, 2009). 
 
This document focuses on young and middle-aged adult women, generally within the age group 18 
to 55, who misuse or are dependent on illicit drugs and who will be referred to in this paper as 
women who use drugs. This report will outline issues encountered by these women, as well as needs 
and responses, likely future developments in the area, major challenges and some implications for 
drug policy and practice. The focus is on treatment and support needs for women who have existing 
drug problems. While sex- and gender-based issues and requirements also need to be considered for 
the development and implementation of appropriate prevention responses, that is beyond the 
scope of this paper. 
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Women who use drugs: general issues, needs and responses 
Women who use drugs face particular issues over and above those experienced by men. For some 
women, these issues may act as obstacles to seeking, entering, engaging with and remaining in 
treatment. 
 
Experiences of stigma are more likely among women who use drugs, who are often perceived as 
contravening ascribed roles, primarily those of mothers and caregivers. Discriminatory, disparaging 
and unsupportive responses from service providers may impede the access and use of required 
services (EMCDDA, 2009; Arsova Netzelmann et al., 2015; Benoit and Jauffret-Roustide, 2016). 
Services should, therefore, create environments that are welcoming, non-judgemental, non-
discriminatory and supportive (Brentari et al., 2011; WHO, 2014). Anonymity and non-punitive 
policies would also encourage women to seek care by removing fear of negative reprisals (EMCDDA, 
2009; Zermiani et al., 2013). 
 
Women who use drugs may also have less social support than their male counterparts (EMCDDA, 
2006; Arsova Netzelmann et al., 2015). For example, women are more likely than men to have 
families of origin that have substance use problems and to have a substance-using partner (Jones et 
al., 2007; Tuchman, 2010). Relationships are important in women’s lives, and drug-using men play a 
role in their female partner’s initiation into and continuation of drug use, including risk of relapse 
(Bloom et al., 2003; Grella et al., 2008; Neale et al., 2014; Arsova Netzelmann et al., 2015), risk of 
blood-borne infections (see Roberts et al., 2010) and exposure to violence (Neale et al., 2014; Benoit 
and Jauffret-Roustide, 2016). Substance-using men may also be more resistant to, and less 
supportive of, their partner’s treatment, and women may fear damaging the relationship if they 
become drug free (UNODC, 2016). Relationships with children are also very important and children 
may play a central role in issues surrounding women’s drug use and recovery (Grella, 2015). Given 
the importance women place on relationships, it is recommended that responses promote healthy 
connections to children, family members and significant others (Bloom et al., 2003). Family 
involvement can be an important adjunct to treatment and can enhance drug treatment 
effectiveness (Greenfield et al., 2007; Espinet et al., 2016; Selbekk, 2016; Slesnick and Zhang, 2016). 
Connections to the community are also important (UNODC, 2004). 
 
Women are generally more biologically susceptible than men to blood-borne infections. For 
example, various features of the female genital tract enhance susceptibility to human 
immunodeficiency virus (HIV) infection (Reis Machado et al., 2014). Women who use drugs also have 
gender-specific vulnerabilities to blood-borne infections (Pinkham et al., 2012). HIV prevalence rates 
are higher among women who inject drugs than among their male counterparts (EMCDDA, 2006; 
Des Jarlais et al., 2012). In comparison with men, women who use drugs are more likely to share 
injecting paraphernalia and to share it with more people (Sherman et al., 2001), trade sex for drugs 
or money and have difficulties in negotiating condom use with sexual partners (Tuchman, 2010). 
Interventions to reduce the risk of blood-borne viruses should address issues such as relationship 
dynamics, housing and employment (to reduce reliance on partners and the need to trade sex), in 
addition to condom use and injecting practices (Pinkham et al., 2012), and should target individuals, 
couples and social networks (El-Bassel et al., 2010). 
 
While not specific to drug users, economic burdens are heavier for women who use drugs than  their 
male counterparts since they experience lower employment and income levels (EMCDDA, 2006). The 
cost of drug treatment may therefore act as a barrier to accessing treatment facilities when services 
are not provided by the state and there is a lack of insurance cover (Grella and Stein, 2013; Arsova 
Netzelmann et al., 2015). Transport costs to and from services may also impede access to treatment 
(Gilchrist et al., 2015). Women therefore require the necessary financial support to access 
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treatment. Responses should also address socioeconomic conditions (Bloom et al., 2003). Responses 
that include education, training and skills development, employment and housing are invaluable for 
many women (UNODC, 2004). 
 
Overall, gender-responsive interventions are recommended to address the issues women face, 
incorporating women’s needs in all aspects of their design and delivery, including structure and 
organisation, location, staffing, programme development, approach and content (UNODC, 2004; 
Covington, 2008; UNODC and WHO, 2016). Gender-responsive programmes may be female only or 
part of a mixed-gender programme that incorporates components and services for women (UNODC, 
2004). 
 
Holistic and comprehensive interventions are required to tackle the multiple issues and needs of 
women (Bloom et al., 2003). Grella (2015) highlights studies that indicate that the provision of a 
wider range of health and social services, particularly when services and needs are matched, is 
accompanied by better outcomes and satisfaction levels for women. Services may be integrated or 
coordinated through collaborative links between multiple services, sectors and disciplines. 
 
Subgroups of women: issues, needs and responses 
Some subgroups of women who use drugs have particular needs, most notably women who have 
experienced or are experiencing trauma and violence, women with comorbidity and women who are 
pregnant, parenting, from ethnic minorities, involved in the sex trade and/or in prison. There are 
often overlaps between these vulnerable groups and women falling within multiple intersecting 
categories may have greater needs. 
Women who have experienced trauma and violence and women who are 
currently experiencing domestic violence 
Women who use substances are more likely than men to have experienced traumatic events, such as 
sexual and physical assault and abuse as children and/or adults (UNODC, 2016) and to be currently 
exposed to intimate partner violence (Downs and Miller, 2002). The experience of trauma can lead 
to the development of post-traumatic stress disorder or other mental health problems and can also 
increase the risk of substance use (Najavits, 2009; Jonas et al., 2011). 
 
This group of women requires interventions delivered in physically and emotionally safe 
environments (Brentari et al., 2011), and additional trauma-informed treatment approaches (Center 
for Substance Abuse Treatment, 2013; UNODC, 2016). Ongoing violence requires a multi-agency, 
multi-sector approach with collaborations between the health and social services and the justice 
sector (Haider, 2008). Female-only services may be needed for women whose male aggressors also 
utilise drugs services to reduce the risk of women encountering the perpetrator. 
 
For women who have experienced trauma and those currently exposed to intimate partner 
violence, trauma-informed treatment approaches are recommended. 
 
Ongoing violence requires collaborations between the health and social services and the 
justice sector. 
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Women with comorbidity 
Approximately half of substance users have co-occurring substance use and mental health disorders 
(EMCDDA, 2015a). The exclusion of people with a dual diagnosis from programmes or services may 
have a greater impact on women than on men, since some psychiatric disorders, such as anxiety, 
depression and post-traumatic stress disorder, and the use of psychoactive medication is more 
prevalent among women (UNODC, 2016). Substance use and mental health disorders should be 
addressed simultaneously using a multidisciplinary approach, with collaborating professionals from 
the drug treatment and the mental health sector working together towards common goals 
(EMCDDA, 2016c). 
 
Pregnant and parenting women 
It is estimated that in each year in Europe approximately 30 000 pregnant women use opioids, and 
the number of pregnant women with other drug problems may be of a similar magnitude 
(Gyarmathy et al., 2009). This is of concern, since drug use during pregnancy is associated with a 
range of adverse effects on the pregnant woman, the unborn child and the newborn (EMCDDA, 
2012a). 
 
Pregnancy and motherhood can be a strong motivator in a woman’s pathway to recovery (EMCDDA, 
2009). However, stigma, shame and guilt (Kensy et al., 2012; Wendell, 2013; UNODC, 2016), and fear 
of having their children removed from their custody, may impede some women from seeking 
treatment and the health and social care required for themselves (EMCDDA, 2009, 2012a; INPUD, 
2014; Arsova Netzelmann et al., 2015; UNODC, 2016), their partners and other family members 
(INPUD, 2014). Women may also be hesitant or unable to obtain the support they need because of 
family and other responsibilities and lack of childcare (Roberts et al., 2010; Grella and Stein, 2013; 
INPUD, 2014). 
 
Interventions for pregnant women should address a broad spectrum of needs and provide 
coordinated interventions in areas that include drug use, gynaecological/obstetric care, infectious 
diseases, mental health and personal and social welfare (Gyarmathy et al., 2009). Multidisciplinary 
care programmes are provided in various countries, and some offer interventions to women who 
use drugs and their children from early pregnancy into childhood (EMCDDA, 2012a). 
For opioid dependence in pregnant women, opioid substitution treatment, in addition to 
psychosocial assistance and other interventions, is recommended and usually provided (EMCDDA, 
2014a; WHO, 2014). Many pregnant women who use opioids want to stop once they discover they 
are pregnant; however, detoxification and withdrawal during pregnancy is not advised. High relapse 
rates contribute towards fetal distress stemming from a sequence of intoxication and withdrawal, 
which is linked with adverse outcomes for the neonate, including miscarriage (WHO, 2009; WHO, 
2014; Zedler et al., 2016). Women should therefore be encouraged to initiate or continue opioid 
substitution medication (WHO, 2009, 2014; Zedler et al., 2016). In Europe, methadone is the most 
commonly prescribed opioid substitution medication (EMCDDA, 2016a). Buprenorphine is also safe 
and effective (Krans et al., 2016) and is associated with superior neonatal outcomes (EMCDDA, 
2014a; Zedler et al., 2016). WHO guidelines (2014) recommend that opioid-dependent pregnant 
women who are already using methadone or buprenorphine should not switch substances unless 
they are not responding well to treatment. 
A range of interventions are available to parenting women including addiction treatment and 
integration of children that had been taken into care into their biological family. Women may also be 
provided with psychosocial support and interventions to empower them and build skills with the aim 
of strengthening the family (EMCDDA, 2012a). Services should also deal with practical concerns and 
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provide childcare and residential services should provide child-friendly accommodation, enabling 
mothers to stay with their children (EMCDDA, 2009). 
 
Service for pregnant women should address a spectrum of needs including 
gynaecological/obstetric care and substitution treatment in the case of opioid dependence. 
 
For parenting women, interventions to build skills and strengthen the family and practical 
concerns such as childcare provision and child-friendly residential services may also be 
required. 
 
Women involved in the sex trade 
Involvement in the sex trade is often intertwined with drug use (Roberts et al., 2010). Estimates of 
female injecting drug users involved in sex work are as high as 20-50 % in eastern Europe (Rhodes et 
al., 2002). Women involved in the sex trade face a range of barriers to accessing support and these 
women require particular efforts to support them in accessing services (DrugScope and AVA, 2013). 
Measures such as evening opening hours, mobile outreach services, childcare and open access 
support can help (DrugScope and AVA, 2013). Stigmatised and negative responses may be greater 
for these women (UNODC, 2016). A non-judgemental and empathetic approach, peer support and 
women-only provision are recommended. Women who trade sex are more likely to experience 
violence and many have limited power to engage in safe sex or safe injecting practices, placing them 
at an increased risk of infections (Azim et al., 2015). A range of interventions from needle exchange 
to treatment and support with employment and housing should be made available (DrugScope and 
AVA, 2013). 
 
Women involved in the sex trade often need additional efforts to support them in accessing 
services, such as evening opening hours and mobile outreach services. 
 
Efforts, such as peer support, are required to counter the additional stigma these women 
may face. 
 
A range of interventions from needle exchange to treatment and support with employment 
and housing should be made available. 
 
 
Women from ethnic minorities 
Ethnic minorities are diverse, incorporating groups from various regions and that practise different 
religions and traditions. Their members also vary in terms of length of residence in the current 
region, from recent migrants, including refugees and asylum seekers, who may not speak the local 
language, to long-term residents and those who were born in the region. In addition to economic 
burdens, social exclusion and over-representation in the criminal justice system, some ethnic 
minority women may also be migrants who have experienced trafficking and trauma as a result of 
war and violence in the places they have left (Fountain et al., 2002). Women from ethnic minorities 
may encounter additional barriers when accessing treatment services, including language difficulties, 
aspects of treatment that are incompatible with religious or cultural practices (UNODC, 2016) and 
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immigration status that affects service eligibility, as well as perceived or actual racism and 
discrimination (Roarty and Saggers, 2009). 
 
Ethnic, cultural and religious diversity needs to be considered when working with this group of 
women (UNODC, 2016). To help women from ethnic minorities attend and engage in treatment 
consideration should be given to outreach workers who can act as cultural mediators (UNODC, 
2016), to interpreter services or service provision in the women’s native language and to cultural 
aspects, so that programmes match the women’s socialisation and cultural practices (Center for 
Substance Abuse Treatment, 2013). 
 
Ethnic, cultural and religious diversity needs to be considered when providing services to 
women from ethnic minorities. 
 
Outreach workers who can act as cultural mediators and interpreters may also be required. 
 
Women in prison 
Many women in prison use drugs. A systematic review, which included mainly US-based studies, 
reported that, in the month before prison entry, 30-60 % of women were dependent on or used 
illicit drugs (Fazel et al., 2006). Compared with women in community-based substance abuse 
treatment, women offenders with substance use problems experience similar issues, although the 
severity of the problems tends to be greater (WHO Regional Office for Europe, 2009; Grella, 2015). 
The complexity of their problems is typically coupled with a lack of appropriate services to meet 
their psychological, social and healthcare needs (EMCDDA, 2012b; Kolind and Duke, 2016). Although 
prisons are high-risk environments for unsafe drug using behaviour and for the transmission of 
blood-borne infections, harm reduction activities, especially access to clean syringes, remain 
controversial (Stover and Hariga, 2016) and are often opposed on the grounds that they are 
perceived to contradict the goal of a drug-free prison (EMCDDA, 2012b). The absence of these 
activities may have a greater impact on women than men, as it has been found that, in the European 
Union, a higher proportion of women prisoners than of male prisoners inject drugs (EMCDDA, 2004). 
 
As a result of their complex needs, these women require diverse interventions while in prison and 
following release (WHO Regional Office for Europe, 2009; Mir et al., 2015). They can benefit from 
gender-responsive, trauma-informed, integrated interventions that address multiple issues in 
addition to substance use, such as trauma, mental health, physical and reproductive health, and 
infectious disease risk behaviours (WHO Regional Office for Europe, 2009; Messina et al., 2010). 
Needle and syringe programmes in prisons are also recommended (UNODC, 2012). At Hindelbank 
women’s prison in Switzerland and Vechta women’s prison in Germany, syringes can be exchanged 
via slot machines (WHO Regional Office for Europe and the Pompidou Group, 2002). Other 
recommendations include drug substitution treatment for women with opioid addiction problems 
(UNODC, 2008) and psychosocial interventions (Covington, 1998). Preparing women for release 
includes supporting them to enhance their housing and financial situations, develop vocational and 
life skills, and rebuild social support networks and family relationships. Throughcare to drug 
treatment in the community is also required (UNODC, 2008). 
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The issues facing women who use drugs in prison are similar to, but more severe than, those 
experienced by other women who use drugs, which reinforces the need for gender-
responsive, trauma-informed, integrated interventions that address multiple issues. 
 
Given the particularly high rates of drug use among female prisoners, needle and syringe 
programmes in prison, preparation for release and throughcare to drug treatment in the 
community are of particular importance. 
 
 
 
 
Key issues 
 
Compared with men who use drugs, women may: 
 
 face higher levels of stigma and shame; 
 carry heavier socioeconomic burdens; 
 receive less social support; 
 be more influenced by their parental role in issues concerning drug use and recovery; 
 have a partner who plays a role in their: 
 drug use initiation, continuation and relapse, 
 exposures to blood-borne infections, 
 exposure to violence. 
 
Compared with men who use drugs, women are more likely to: 
 
 have gender-specific vulnerabilities to blood-borne infections; 
 have experienced a traumatic event; 
 have anxiety, depression or post-traumatic stress disorder and use psychoactive medication. 
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Summary of general recommended responses 
 
Responses should: 
 
 be gender responsive, incorporating women’s needs in all aspects of their design and 
delivery; 
 
 be delivered in environments that are welcoming, non-judgmental, supporting and physically 
and emotionally safe; 
 
 be holistic and comprehensive in order to address the multiple issues that women face; 
 
 promote healthy connections to children, family members, significant others and the 
community; 
 
 address socioeconomic conditions. 
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Examples of interventions for women who use drugs 
Women who have experienced trauma 
In the women-only, abstinence-based, trauma-informed, residential rehabilitation service in the 
United Kingdom, women participate in a range of group therapies based on a manualised, trauma-
informed treatment programme. The women are also offered individual counselling and eye 
movement desensitisation and reprocessing, which is used to help with the distress associated with 
trauma and family support in accordance with their specific needs. In addition, the residents can 
benefit from a structured programme comprising education skills, training and recreational 
activities, and may attend peer support groups (Narcotics Anonymous and Alcoholics Anonymous). 
After successful completion of treatment, women move into their own accommodation or into one 
of the organisation’s resettlement houses; ongoing support from the service and other organisations 
can still be accessed if required (Tompkins and Neale, 2016). 
Women with comorbidity 
In Malta, the Female Dual Diagnosis Unit is a preliminary residential unit where women generally 
stay for maximum of six weeks. During this time, women undergo a detoxification programme and 
receive services from a multidisciplinary team, which includes a consultant psychiatrist, a doctor, a 
nurse, a psychologist and a social worker. Women may also receive external services, to which they 
are accompanied, including services to assist them with finding employment (Dalli, 2014; Camilleri, 
20171). 
Pregnant and parenting women 
In Hungary, the Józan Babák Klub targets pregnant women or mothers with a child under the age of 
two. It takes a three-step approach. In step 1, women can contact a member of the Józan Babák 
Klub, which is self-help group that provides information about the available services. In the second 
step, medical, legal, social and psychological services can be utilised on an anonymous basis from the 
Józan Babák Klub. At this stage, if the pregnant or parenting woman participates in professional 
counselling for an average of 60 minutes over eight sessions, she receives a grant of EUR 11 per 
session. In step 3, the organisation facilitates contact with the required healthcare, social or legal 
services and, in the case of pregnant women, with prenatal services. During steps 2 and 3, a member 
of the Józan Babák Klub self-help group will accompany the women to any of the services, if 
requested (Tarján, 2012). 
The Kangaroo project, a programme in Belgium targeting parents within a residential setting, aims, 
in part, to maintain or enhance parents’ links with their children. Women are supported in their 
parenting role. During the day, children attend nursery, kindergarten or school, while mothers 
attending the therapeutic programme undertake activities. The project provides information to 
parents, facilitates parent-child activities and thematic groups, and offers individual consultation and 
someone to accompany parents to appointments (Deprez et al., 2011; Ferri et al., 2015). 
In the United Kingdom, the Family Drug and Alcohol Court service provides an alternative to care 
proceedings in cases in which parental substance misuse plays a major role. It directs parents 
through a different pathway to help parents cease or stabilise substance use to keep families 
together and enhance child and parent outcomes. Following assessment, diverse services 
                                                            
1 Camilleri, Marthese (Personal communication, 15 March 2017). 
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appropriate to the various needs of each family are provided. They are delivered by a 
multidisciplinary team, which includes a nurse, a substance misuse worker, social workers, 
psychiatrists, a family therapist and a service manager. Issues dealt with may include substance use, 
physical and mental health, parenting, relationships with children and other family members, 
domestic violence and housing (The Tavistock and Portman NHS Foundation Trust, n.d.). An 
evaluation has highlighted positive aspects of the service (Alrouh et al., 2014). 
The SAOL project is a community based project in Ireland. It provides services to women currently 
attending a drug programme. One of its aims is to educate and train women to support them in 
achieving employment. Childcare assistance is also provided in this regard through a children’s 
centre, which focuses on early childhood education (North Inner City Drugs Task Force, 2014). 
Women in prison 
A drug recovery wing within a women’s prison in the United Kingdom, which was evaluated more 
positively than one other in a process and impact evaluation, was described as being physically 
separate from the rest of the prison. The programme is run by drug workers within an environment 
that provides physical and emotional safety. It takes a holistic approach and time is dedicated 
towards recovery, as well as education and/or employment issues, community activities and physical 
activity. Women can also access drug treatment and general support from agencies outside prison 
(Grace et al., 2016). 
The Quartier Intermédiaire Sortantes is a pre-release unit based near Paris for women in prison who 
have drug use-related problems. It prepares women in the last month of imprisonment for release. 
The internal and external staff who conjointly run the voluntary programme provide information, 
advice and support on a variety of topics, including health issues (e.g. health promotion, healthcare 
and harm reduction); support networks (e.g. re-establishing links with family and children; 
supporting agencies for sex workers); and training in everyday skills (e.g. household tasks, cooking 
and financial management). External experts help create links that can be used within the 
community following release (EMCDDA, 2006). 
Women involved in the sex trade 
Ragazza is an organisation in Germany offering low-threshold services to women involved in sex 
work. The all-female multi-disciplinary team includes social workers, nurses, educational assistants 
and doctors. The association provides a contact point that offers anonymous counselling and advice 
on a range of issues including safer drug use, safer sexual practices, safer work, pregnancy and 
family matters and advice on treatment interventions, as well as housing, financial and legal issues. 
Case management and support, which may include accompanying women to various appointments, 
is also offered. The organisation also has a drug consumption room, which aims to minimise harm to 
drug users and reduce drug emergencies through the provision of clean needles, hygienic conditions 
for drug use, emergency treatment, if required, and advice on safe drug use. Treatment of wounds, 
infections and medical care, including gynaecological care, is also provided within a medical room. In 
addition, the organisation offers emergency beds during specified times and engages in outreach 
street work, offering supplies (condoms and lubricant), hot and cold drinks, on-the-spot advice, 
information on the services provided by Ragazza and contacts to other services (information 
available from the Ragazza website following links under the section ‘Offer’; Ragazza, n.d.). 
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Future developments in the area, challenges and 
implications for drug policy and practice 
Future developments 
With likely reductions in Europe in the discrepancy between men and women in the demand for 
drug services, further implementation and expansion of services that aim to meet the needs of 
women is required. This may be facilitated by the increasing awareness and promotion of gender-
responsive policies and programmes at various levels. In the light of changing trends in drug use 
(EMCDDA, 2016a), new developments may be required in interventions that cater for women who 
have problems related to the use of cannabis, which is the substance that now creates the most 
demand for treatment in Europe (EMCDDA, 2015b, 2016a), as well as prescription drugs, new 
psychoactive substances (NPS) and polydrug use. A focus on providing interventions that also cater 
for older women may be necessary. In European countries, there have been developments in 
intervention delivery methods. Internet-based drug treatment, which has been defined as 
‘specifically elaborated or adapted, structured drug treatment interventions, offered on and 
communicated over the internet’ (EMCDDA, 2014b, 1), can be expanded to provide an array of 
women-centred activities that can be used alone or as an adjunct to other interventions. These may 
appeal specifically to some groups of women who are not fully covered by specialised drug services 
and may help overcome some logistical and structural barriers in accessing traditional treatment by 
reducing or eliminating issues such as transport requirements, inflexible opening hours and childcare 
needs. It may also reduce fear of being seen near drug treatment centres. 
Challenges and implications for drug policy and practice 
It is necessary to ensure that policies and practices are gender mainstreamed and that women who 
use drugs participate in the planning, formation and development of programmes and policies 
(INPUD, 2014). Women must be empowered to participate. Current policies need to be examined 
and amended accordingly. To fully address the issue of drug use among women, the misuse of 
prescription drugs must be included in policies and strategies (Women’s Health Council, 2009; Clark, 
2015). 
 
Funding is a challenge in many European countries (Cyprus Anti-Drug Council and Cyprus Monitoring 
Centre for Drugs and Drug Addiction, 2012; Ferri et al., 2015). Across Europe many drug services are 
funded by national, regional and local authorities and by non-governmental organisations (EMCDDA, 
2011). In times of budgetary constraints, programmes for women may be neglected because women 
make up the minority of drug service users. It has also been suggested that gender-responsive 
programmes cost more (Burgdorf et al., 2004), although there is not sufficient evidence to 
substantiate this. Examining the cost-effectiveness of interventions that meet the needs of women 
within the diverse settings found across Europe is necessary to help ensure that interventions 
provided are effective and economically viable. Securing long-term funding is also necessary (Ferri et 
al., 2015). 
 
There are still large knowledge gaps in various aspects of women’s drug use. The field is hindered by 
the fact that studies do not always include women or consider sex and gender in their design, and do 
not always disaggregate data by gender, conduct gender analyses or address gender issues (UNODC, 
2004; Roberts et al., 2010; Greenfield et al., 2011; Springer et al., 2015). In addition, a great deal of 
the research and responses available in relation to women who use drugs is oriented towards opioid 
users of child-bearing age. It is also often limited to those that address women’s roles as mothers 
(e.g. Rolando et al., 2016). These issues, coupled with changing trends in drug use, necessitate 
further research on a broad range of areas (e.g. including prescription drugs, NPS and polydrug use) 
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and should include women of all ages from various subgroups (UNODC, 2016). The relevance and 
transferability of responses found to be effective elsewhere and the adaption required also needs to 
be examined. Research on issues including and specific to women who use drugs should, therefore, 
be encouraged to ensure that women receive high-quality, evidence-based responses. 
 
The complex, overlapping issues faced by many women who use drugs requires coordinated and 
integrated services to address issues beyond drug use. These issues are often compartmentalised 
and networks separated. Across Europe, for example, there is often separation between drug use 
and mental health networks (EMCDDA, 2016c). Interdisciplinary coordination, collaborations and 
multifaceted approaches between settings and sectors are challenging (González-Guarda et al., 
2011). Collaboration often relies on the goodwill of local stakeholders and cooperation at the 
individual level. To address this challenge, embedding collaboration into policies and strategies at 
higher levels is an important initial step (Benoit and Jauffret-Roustide, 2016). 
 
Staff are required to have appropriate attitudes (non-judgemental, non-discriminatory and 
supportive) and adequate competency to encourage women who use drugs to access and engage 
with services and to intervene with them effectively (Center for Substance Abuse Treatment, 2013). 
This includes awareness of the unique needs of women (UNODC, 2016) and the importance of 
gender mainstreaming, together with the provision of required training (Rolando et al., 2016). In 
terms of drug service providers, the importance of knowledge and skills in areas other than 
substance use has been noted (e.g. Timko, 2012; Gilchrist et al., 2015). Service providers working in 
settings that intersect with drug use also need to embrace the same attitudes and have knowledge 
concerning drug use and responses (Brentari et al., 2011). Staff competency is facilitated through 
appropriate education, training, skills development and adequate supervision, and practitioners and 
policymakers need to ensure that this is addressed. Community agencies (e.g. child welfare system 
and healthcare providers) also require training to enhance awareness, identify women who use 
drugs and provide interventions or refer as necessary (e.g. UNODC, 2004; Clark, 2015).  
Some considerations for drug policy and practice 
 
The following are recommended: 
 
 implement and further expand services that meet the needs of women where indicated; 
 enhance understanding of drug use trends, sociodemographic factors and issues faced by 
women within a given region to develop appropriate responses; 
 reduce knowledge gaps by ensuring that research addresses gender issues and considers gender 
in all aspects of its design and analysis; 
 ensure that existing and planned policies and practices are gender mainstreamed; 
 facilitate the participation of women who use drugs in the planning, formation and development 
of policies and programmes; 
 include the misuse of prescription drugs in policies and responses; 
 provide coordinated and integrated services to address issues beyond drug use, which may 
require embedding collaboration into policies and strategies; 
 ensure that staff from specialised drug services and other services, fields and disciplines who 
come into contact with women who use drugs have appropriate attitudes, knowledge and skills 
to enable women to receive appropriate responses; 
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 secure long-term funding for relevant programmes for women; 
 conduct studies that examine the cost-effectiveness of interventions so that the interventions 
provided are effective and economically viable. 
 
Conclusion 
Women who use drugs face a number of issues that vary in extent and nature compared with those 
experienced by their male counterparts. They have greater experiences of stigma, shame and 
discriminatory responses; have less social support; are more influenced in issues relating to drug use 
and recovery by their parental role and through their partners; and are at a greater risk of exposure 
to violence and blood-borne infections. In general, responses for women should be gender 
responsive, incorporating women’s needs in all aspects of their design and delivery; be delivered in 
environments that are welcoming, non-judgemental, supporting and physically and emotionally safe; 
be holistic and comprehensive; promote healthy connections to children, family members, 
significant others and the community; and address socioeconomic conditions. There are also 
subgroups of women with additional issues and needs that need to be considered. 
 
Several international instruments and documents focused on gender differences in drug responses 
have been drawn up and an array of policy statements, drug strategies, best practices, guidelines, 
standards and reports at various levels promoting responses that address the needs of women are 
available (UNODC, 2004; Salvati and Sabet, 2015; Shihadeh, 2015). However, gaps still exist. There 
are concerns over coverage of women’s service in Europe (Cyprus Anti-Drug Council and Cyprus 
Monitoring Centre for Drugs and Drug Addiction, 2012) and the nature of services provided. For 
example, many interventions delivered to women were designed with men in mind. Gender-
responsive interventions have tended to focus more heavily on opioid use and women’s role as 
child-bearers and carers, paying less attention to women who use other drugs, are older or who 
form part of other subgroups. Gaps also include compartmentalisation of services for overlapping 
issues and the capacity of service providers. 
 
Recommended actions include reducing knowledge gaps in relation to women’s drug use and 
appropriate responses; increasing awareness and promotion of gender-responsive policies and 
programmes; introducing and expanding services that meet the needs of women who use drugs, 
irrespective of drug of use, age or subgroup; gender mainstreaming of policies and practices; 
ensuring the participation of women who use drugs in policy and programme development; and 
providing coordinated and integrated services to address issues beyond drug use. It is also necessary 
to secure long-term funding for programmes and ensure adequate staff competency and capacity. 
Within the area of women’s drug use, further epidemiological studies, sex-specific biomedical 
research, studies on treatment gaps, needs assessments, programme evaluations and cost-
effectiveness studies are required. In particular, it is important to examine interventions that are 
effective for older women and women who are polydrug users and who use cannabis, prescription 
drugs and NPS. Such efforts, together, can help to address existing shortcomings and limitations, and 
ensure that effective, evidence-based interventions for women become the norm for the benefit of 
women and those impacted by their drug use. 
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